Early benefit assessment: Detailed analysis of all G-BA resolutions
The AMNOG monitor provides current, well-founded analyses of all early benefit assessments and an overview of the negotiated reimbursement prices in Germany. It is an indispensable tool for HTA, market access and pricing managers.
List of all G-BA Resolutions
The AMNOG monitor includes detailed analyses of every single benefit assessment since 2011. more >>
Interactive Analysis
Our comprehensive online analysis tool helps answer your individual questions. more >>
Intelligent search
Search for answers in all G-BA resolutions, justifications, IQWiG assessments and much more >>
Reimbursement Price Trends
See the development of manufacturers' prices and yearly therapy costs of all products with negotiated reimbursement prices. more >>
"Interactive analysis" step by step
A quick tour through the AMNOG Monitor's powerful analysis tool. more >>
"Detailed analysis" step by step
A tour through the structure of our quantitative and qualitative analyses of each G-BA resolution. more >>
Resolutions April 2026
Dear readers of the AMNOG Monitor,
Following our report last month on the 66 recommendations made by the Health Finance Committee to stabilise the statutory health insurance (GKV) system, the government's draft version on the austerity package – the so-called Statutory Health Insurance Contribution Stabilisation Act (GKV-BSG) – is now available.
The measures presented are based on two key principles: a) increases in expenditure will be limited to the growth in real revenue; b) only those services with a demonstrable medical benefit will be reimbursed. The proposed measures are expected to generate savings of just under €20 billion per year. Patients, hospitals, health insurance funds and the pharmaceutical industry must expect significant losses in order to achieve this savings potential. The planned changes are set out in detail in the 157-page draft bill (see link). The pharmaceutical industry is expected to make a substantial contribution to this:
| Measure | change in Mio. € per year | |||
|---|---|---|---|---|
| 2027 | 2028 | 2029 | 2030 | |
| Dynamic manufacturer rebate 7% + annual adjustment for 2027 + 3.5% |
-1,230 | -2,110 | -3,885 | -6,115 |
| Price-volume agreement according to Dapagliflozin arbitration court |
- | -67 | -167 | -500 |
| Selective contracts for 5 medical groups* | - | -200 | -400 | -600 |
| Orphan Drug Privilege (30 Mio. € turnover limit unchanged) |
- | - | - | - |
| Price moratorium from 2010 prolonged until 2030 | - | - | - | - |
| Abolition of combination rebate (-20%) | +60 | +160 | +185 | +200 |
| Abolition of rebate guard rails | +167 | +333 | +500 | +667 |
*Estimated savings or additional costs resulting from planned changes in accordance with the draft bill; selective contracts until 2030 for five AM groups: CGRP antagonists, as well as JAK-, PARP-, PCSK9- and PD-L1/PD-1 inhibitors
In April, there were 7 new decisions on early benefit assessment (Fig. A), and 8 new procedures were initiated (Fig. B). Price changes are shown in Fig. C, and the current EU HTA procedures are listed via the link below.
Two new procedures have been opened: taletrectinib for the treatment of ROS1-positive patients with advanced NSCLC, and zamtocabtagene autoleucel for large B-cell lymphoma (LBCL), bringing the total number of ongoing EU HTA procedures to 15.
We will be updating the layout of the AMNOG Monitor to make it more modern and user-friendly, and will be introducing a range of new features, which we would be delighted to demonstrate to you in a free training session.
Please arrange a training session – feel free to suggest a specific date and time.
We look forward to seeing you.
With best regards
Dr. Johannes Hankowitz
Munich, 20th April 2026